Columnist Anna Jeter describes her fast, and perhaps uncommon, pulmonary hypertension diagnosis journey, which lasted about ...

November is Pulmonary Hypertension Awareness Month, and the American Lung Association, with support from Merck, is raising awareness about one form of the condition: pulmonary arterial hypertension ...

Pulmonary hypertension treatment can help slow disease progression, ease symptoms, and improve quality of life for people with the disease.

About 1% of the global population has pulmonary hypertension, which currently has no cure. The condition is more common in females, and scientists believe it may be due to the hormone estrogen.

A machine learning model using basic clinical data can predict PH risk, identifying key predictors like low hemoglobin and elevated NT-proBNP. Researchers have developed a machine learning model that ...

Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone morphogenetic protein pathway signaling is ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.

In treatment-naïve patients with PAH, initial monotherapy improves exercise capacity, hemodynamics, and outcomes when compared with those noted among untreated patients. In patients who are newly ...

Sotatercept, an activin-signaling inhibitor, reduces morbidity and mortality among patients with long-standing pulmonary arterial hypertension. Its effects in patients with pulmonary arterial ...

Researchers estimate that about 1% of the global population has pulmonary hypertension — a disease caused by high blood pressure in the blood vessels that deliver oxygen to the lungs. Past studies ...